| 1982 |
Graduated from Chiba University School of Medicine, engaged in clinical practice as a doctor. |
| 1984 |
Graduated from Chiba University School of Medicine, engaged in clinical practice mainly in diabetes and clinical nutrition at National Center of Neurology and Psychiatry (formerly Kohnodai Hospital) and Utsunomiya Hospital for 11 years. |
| 1988 |
Engaged in corporate screening, financial engineering, corporate planning, and sales to corporations including public organizations and financial institutions at Shinkin Central Bank. |
| 1992 |
Graduated from Nagaoka University of Technology, joined Mochida Pharmaceutical Co., Ltd. as a hospital-focused MR. |
| 1994 |
Graduated from Nagaoka University of Technology, joined Mochida Pharmaceutical Co., Ltd. as a hospital-focused MR. |
| 1996 |
Graduated from Doshisha University Faculty of Law, joined Sumitomo Corporation. Responsible for joint ventures for US high-tech startups' entry into Japan, business development, product development, and promotion for Silicon Valley companies focusing on the CATV industry. Left the company, entered the University of Virginia MBA program in 2005, and obtained an MBA. From 2007, engaged in business strategy and organizational reform at Rakuten, Inc. In 2008, left the company and participated in launching an online community for healthcare professionals. |
| 2001 |
Joined CTC Laboratory Systems Inc. (now Itochu Techno-Solutions Corporation), engaged in pharmaceutical research and development, proposing advanced technology IT solutions and sales of SI projects, serving as sales manager and marketing manager. |
| 2010 |
Worked in corporate strategy headquarters, responsible for multiple business leaders and venture investments at Rakuten, Inc. |
| 2011 |
Founded Welby in 2011 and became co-CEO. |
| 2011 |
Founded Welby and became co-CEO. |
| 2013 |
Worked at Torii Pharmaceutical Co., Ltd. in R&D, drug information, and customer service; served as director and overall manufacturing and sales manager from 2013, responsible for quality and safety assurance of products. |
| 2014 |
Worked at Frontier Turnaround Inc. (now Frontier Management Inc.), as dispatched director and CXO for listed companies and fund-invested companies, involved in corporate value enhancement, restructuring, M&A, and alliances. |
| 2016 |
Joined Daiichi Sankyo Co., Ltd., engaged in digital transformation and digital health technology advisory as Innovation & DX担当. |
| 2016 |
Established a management consulting firm, serving as CEO (current), and as CEO of a deep tech venture originating from a materials university (current). |
| 2022 |
Joined Fronteo Inc., led the launch of AI drug discovery business as Head of Life Science AI Division, promoted medical DX and AI medical device businesses. |
| 2023-10 |
Joined Welby in October 2023. |
| 2024-03 |
Utilizing experience in providing information to patients and healthcare professionals, appointed director in March 2024. |
| 2026-03 |
Appointed director in March 2026. |
